Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

BACKGROUND: In the advanced urothelial carcinoma (aUC) scenario there are no consistent immune checkpoint blockade predictive biomarkers. Recently a novel pan-tumor molecular tissue-based biomarker, the Immunotherapy Response Score (IRS), has been proposed. We conducted a retrospective study to vali...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreiro-Pantín, M., Anido-Herranz, U., Betancor, Y.Z., Cebey-López, V., León-Mateos, L., García-González, J., García-Acuña, S.M., Fernández-Díaz, N., Tubio, J.M.C., López-López, R., Ruiz-Bañobre, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485401/
https://www.ncbi.nlm.nih.gov/pubmed/37516059
http://dx.doi.org/10.1016/j.esmoop.2023.101611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485401/
https://www.ncbi.nlm.nih.gov/pubmed/37516059
http://dx.doi.org/10.1016/j.esmoop.2023.101611

Ejemplares similares